Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;26(21):2100438.
doi: 10.2807/1560-7917.ES.2021.26.21.2100438.

Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021

Iván Martínez-Baz  1   2   3 , Ana Miqueleiz  3   4 , Itziar Casado  1   2   3 , Ana Navascués  3   4 , Camino Trobajo-Sanmartín  3   4 , Cristina Burgui  1   2   3 , Marcela Guevara  1   2   3 , Carmen Ezpeleta  3   4 , Jesús Castilla  1   2   3 ; Working Group for the Study of COVID-19 in Navarra  5
Collaborators, Affiliations

Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021

Iván Martínez-Baz et al. Euro Surveill. 2021 May.

Abstract

COVID-19 vaccine effectiveness was evaluated in close contacts of cases diagnosed during January-April 2021. Among 20,961 contacts, 7,240 SARS-CoV-2 infections were confirmed, with 5,467 being symptomatic and 559 leading to hospitalisations. Non-brand-specific one and two dose vaccine effectiveness were respectively, 35% (95% confidence interval (CI): 25 to 44) and 66% (95% CI: 57 to 74) against infections, 42% (95% CI: 31 to 52) and 82% (95% CI: 74 to 88) against symptomatic infection, and 72% (95% CI: 47 to 85) and 95% (95% CI: 62 to 99) against COVID-19 hospitalisation. The second dose significantly increased effectiveness. Findings support continuing complete vaccination.

Keywords: COVID-19; COVID-19 vaccine; SARS-CoV-2; close contact; cohort study; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared

Figures

Figure
Figure
Flowchart of the selection of close contacts of COVID-19 cases for the prospective cohort study on vaccine effectiveness, Navarre, Spain, January–April 2021 (n = 20,961 contacts selected)
See this image and copyright information in PMC

References

    1. European Center for Disease Control and Prevention (ECDC). Case definition for coronavirus disease 2019 (COVID-19, as of 3 December 2020. Stockholm: ECDC. [Accessed: 26 May 2021]. Available from: https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition
    1. Ministerio de Sanidad. Estrategia de detección precoz, vigilancia y control de COVID-19. Actualizado a 26 de febrero de 2021. [Strategy for early detection, surveillance and control of COVID-19. Updated 26 February 2021]. Madrid: Spanish Ministry of Health. Spanish. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual...
    1. European Centre for Disease Prevention and Control (ECDC). Contact tracing: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases in the European Union –third update, 18 November2020. Stockholm: ECDC; 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-contac...
    1. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MA, et al. Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. Clin Microbiol Infect. 2021;27(3):472.e7-10. 10.1016/j.cmi.2020.11.004 - DOI - PMC - PubMed
    1. European Centre for Disease Prevention and Control (ECDC). Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK. 19 November 2020. ECDC: Stockholm; 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Options-use-of-...

Publication types

LinkOut - more resources